Skip to main content
    N

    Neuphoria Therapeutics Inc (NEUP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.48
    -0.07 (-2.75%)

    Market Cap: $13.80M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Neuphoria Therapeutics Inc (NEUP) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Neuphoria Therapeutics are Psyence Biomedical Ltd. Common Shares (PBM), Quoin Pharmaceuticals Ltd DRC (QNRX) and Quantum BioPharma (QNTM). By market cap, Neuphoria Therapeutics ranks 8th of the 13 companies on this page; Pelthos Therapeutics (PTHS) is the largest at $29.24M.

    Peer Comparison

    NEUP's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Neuphoria Therapeutics (NEUP)$13.80MN/AN/A0.0%N/A0.0%0.00%
    Psyence Biomedical Ltd. Common Shares (PBM)$12.00MN/AN/A0.0%N/A0.0%0.00%
    Quoin Pharmaceuticals Ltd DRC (QNRX)$17.78MN/AN/A0.0%N/A0.0%0.00%
    Quantum BioPharma Ltd. (QNTM)$10.35MN/AN/A0.0%-150.1%0.0%0.00%
    Context Therapeutics Inc (CNTX)$16.61MN/AN/A0.0%N/A0.0%0.00%
    Vyne Therapeutics Inc (VYNE)$19.07MN/AN/A0.0%N/A-57.4%0.00%
    Passage Bio Inc (PASG)$13.68MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Cyclerion Therapeutics Inc (CYCN)$15.73MN/AN/A0.0%N/A-43.2%0.00%
    Pluri Inc. (PLUR)$15.09MN/A8.7x0.0%-650.8%-15.8%0.00%
    Pelthos Therapeutics Inc. (PTHS)$29.24MN/A0.5x-199.5%-95.4%0.0%0.00%
    Vyome Holdings, Inc. (HIND)$11.09MN/AN/A0.0%N/A67.5%0.00%
    VistaGen Therapeutics Inc (VTGN)$8.01MN/A3.4x0.0%N/A-46.5%0.00%
    Peer median$14.80MN/A6.1x0.0%-150.1%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Neuphoria Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Psyence Biomedical Ltd. Common Shares (PBM)
    Psyence Biomedical Ltd. (PBM) is an innovative biotechnology company focused on harnessing the therapeutic potential of psychedelic compounds to address mental...
    Quoin Pharmaceuticals Ltd DRC (QNRX)
    Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases...
    QNRX competitors
    Quantum BioPharma Ltd. (QNTM)
    Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on advancing transformative therapies for oncology and autoimmune diseases.
    QNTM competitors
    Context Therapeutics Inc (CNTX)
    Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid...
    CNTX competitors
    Vyne Therapeutics Inc (VYNE)
    VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology.
    Passage Bio Inc (PASG)
    Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases.
    PASG competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Cyclerion Therapeutics Inc (CYCN)
    Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development...
    Pluri Inc. (PLUR)
    Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy...
    PLUR competitors
    Pelthos Therapeutics Inc. (PTHS)
    Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
    PTHS competitors
    Vyome Holdings, Inc. (HIND)
    Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States...
    HIND competitors
    VistaGen Therapeutics Inc (VTGN)
    VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential...
    VTGN competitors

    Frequently Asked Questions About NEUP

    Who are Neuphoria Therapeutics' main competitors?

    The companies most similar to Neuphoria Therapeutics include Psyence Biomedical Ltd. Common Shares (PBM), Quoin Pharmaceuticals Ltd DRC (QNRX), Quantum BioPharma (QNTM), Context Therapeutics (CNTX) and Vyne Therapeutics (VYNE), listed from the closest match.

    Who is Neuphoria Therapeutics' biggest competitor?

    Pelthos Therapeutics (PTHS) is the largest of the similar companies at $29.24M; Psyence Biomedical Ltd. Common Shares (PBM) is the closest match by business profile, size, sector and industry.

    How does NEUP stock compare with its competitors?

    NEUP's net margin is 0.0% against a peer median of 0.0%.

    Which of Neuphoria Therapeutics' competitors pays a higher dividend?

    Neuphoria Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Neuphoria Therapeutics bigger than its competitors?

    No. Neuphoria Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Pelthos Therapeutics (PTHS) at $29.24M.